Global Leading Market Research Publisher QYResearch announces the release of its latest report “Blonanserin API – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Blonanserin API market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Blonanserin API was estimated to be worth US$ 68 million in 2025 and is projected to reach US$ 126 million, growing at a CAGR of 9.3% from 2026 to 2032.
In 2024, global Blonanserin API production reached approximately 26 tons, with an average global market price of around US,300 per kilograms. Blonanserin API is the active pharmaceutical ingredient used to manufacture blonanserin drug products. It is an atypical antipsychotic that exerts therapeutic effects primarily by antagonizing dopamine D2 and serotonin 5-HT2A receptors. Clinically indicated for the treatment of schizophrenia and related psychiatric disorders, the API is provided to formulation manufacturers in pharmaceutical-grade quality (meeting GMP and pharmacopoeial standards) and offered in various purity grades and packaging forms for tablet or other dosage form production.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6095420/blonanserin-api
1. Industry Pain Points and the Shift Toward Atypical Antipsychotics
Schizophrenia affects approximately 24 million people globally, requiring lifelong treatment with antipsychotic medications. First-generation (typical) antipsychotics cause extrapyramidal symptoms (EPS) and tardive dyskinesia due to high dopamine D2 receptor affinity. Blonanserin API is an atypical antipsychotic with balanced dopamine D2 and serotonin 5-HT2A antagonism, offering lower EPS risk. For pharmaceutical manufacturers and healthcare systems, blonanserin provides an effective treatment option with improved tolerability.
2. Market Size, Production Volume, and Growth Trajectory (2024–2032)
According to QYResearch, the global blonanserin API market was valued at US$ 68 million in 2025 and is projected to reach US$ 126 million by 2032, growing at a CAGR of 9.3%. In 2024, global production reached approximately 26 tons with an average selling price of US$ 2,300 per kilogram. Market growth is driven by three factors: increasing schizophrenia prevalence (global, aging population), generic drug expansion (blonanserin patent expiration), and emerging markets (China, India) adopting atypical antipsychotics.
3. Six-Month Industry Update (October 2025–March 2026)
Recent market intelligence reveals four notable developments:
- Generic blonanserin approvals: Chinese manufacturers (HeBei Guolong, Zhejiang Guobang, Zhejiang Jinhua Conba, Hunan Xiangzhong) received NMPA approvals for generic blonanserin API, driving 15% price reduction.
- Expanded clinical indications: Clinical trials for bipolar disorder (manic episodes) and treatment-resistant depression (adjunctive) are ongoing, potentially expanding addressable market by 30%.
- Long-acting injectable (LAI) development: Blonanserin LAI formulations (monthly injection) in Phase 3 trials, requiring higher API volumes (milligram-to-gram scale).
- API capacity expansion: Japanese and Chinese manufacturers increased production capacity by 25% collectively, ensuring supply chain resilience.
4. Competitive Landscape and Key Suppliers
The market includes Japanese innovator and Chinese generic manufacturers:
- Sumitomo Pharma (Japan – innovator, Lonasen brand), HeBei Guolong Pharmaceutical (China), Kaneka Corporation (Japan), Tianish Laboratories (India), Cerata Pharmaceuticals (India), Lizhu Synthetic Pharmaceutical (China), Zhejiang Guobang Pharmaceutical (China), Zhejiang Jinhua Conba BIO-PHARM (China), Hunan Xiangzhong Pharmaceutical (China).
Competition centers on three axes: purity (≥98% vs. ≥99%), impurity profile (pharmacopoeial compliance), and cost per kilogram.
5. Segment-by-Segment Analysis: Type and Application
By Purity
- Purity ≥98%: Standard grade for generic tablets. Lower cost, suitable for most formulations. Account for ~60% of market.
- Purity ≥99%: High-purity grade for innovator and premium generics. Higher cost, stricter impurity limits. Account for ~40% of market.
By Dosage Form
- Tablets: Largest segment (~80% of market). Oral blonanserin (2 mg, 4 mg, 8 mg tablets).
- Powders: (~15% of market). API for compounding, R&D, and LAI development.
- Others: Oral solutions, patches. ~5% of market.
User case – Generic blonanserin tablet launch (China) : A Chinese pharmaceutical company (HeBei Guolong) launched generic blonanserin tablets (4 mg) at 30% lower price than innovator (Sumitomo). API purity: 98.5% (meeting Chinese Pharmacopoeia). Bioequivalence study demonstrated equivalent pharmacokinetics (AUC, Cmax within 80-125%). The generic captured 25% market share within 12 months.
6. Exclusive Insight: Blonanserin vs. Other Atypical Antipsychotics
| Parameter | Blonanserin | Risperidone | Olanzapine | Aripiprazole |
|---|---|---|---|---|
| D2 receptor affinity (Ki, nM) | 0.14 | 0.16 | 0.31 | 0.34 |
| 5-HT2A affinity (Ki, nM) | 0.81 | 0.17 | 0.27 | 0.26 |
| D2/5-HT2A ratio | 0.17 | 0.94 | 1.15 | 1.31 |
| EPS risk | Low | Moderate | Low | Very low |
| Weight gain risk | Low | Moderate | High | Low |
| Metabolic syndrome risk | Low | Moderate | High | Low |
| Prolactin elevation | Low | High | Low | Low |
| Sedation | Low | Moderate | High | Low |
Technical challenge: Controlling impurity profile (related substances) during API synthesis. Blonanserin synthesis involves multiple steps; impurities (des-fluoro, N-oxide, dimers) must be <0.1-0.5%. Chinese manufacturers (HeBei Guolong, Zhejiang Guobang) have optimized synthetic routes to meet ICH Q3A guidelines.
User case – Impurity control in generic API: A generic manufacturer (Zhejiang Guobang) developed a new blonanserin synthesis with lower impurity levels (total impurities <0.3%, single impurity <0.1%) vs. innovator (0.5%). The API received regulatory approval in China and is now exported to India and Southeast Asia.
7. Regional Outlook and Strategic Recommendations
- China: Largest and fastest-growing market (50% share, CAGR 10%). HeBei Guolong, Zhejiang Guobang, Zhejiang Jinhua Conba, Hunan Xiangzhong, Lizhu Synthetic. Large schizophrenia population (8+ million), generic drug expansion, government support for API manufacturing.
- Japan: Second-largest (25% share, CAGR 8%). Sumitomo Pharma (innovator), Kaneka Corporation. Established market, patent expiration driving generic entry.
- India: Growing market (15% share, CAGR 9%). Tianish Laboratories, Cerata Pharmaceuticals. Emerging generic API manufacturing hub.
- Rest of World: Europe, Latin America, Middle East. Smaller but growing.
8. Conclusion
The blonanserin API market is positioned for strong growth through 2032, driven by schizophrenia prevalence, generic expansion, and emerging market adoption. Stakeholders—from API manufacturers to formulation companies—should prioritize high-purity (≥99%) for premium generics and innovator supply, impurity control for regulatory compliance, and capacity expansion for growing demand. By enabling atypical antipsychotic production, blonanserin API provides effective schizophrenia treatment with improved tolerability.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
